Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Bader

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Nature Chemical Biology|July 23, 2021
HUWE1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domainDaniel B Grabarczyk, Olga A Petrova, Luiza Deszcz, et al.
Journal of Medicinal Chemistry|February 26, 2016
Structure-Based Design of an in Vivo Active Selective BRD9 InhibitorLaetitia J Martin, Manfred Koegl, Gerd Bader, et al.
Nature Communications|April 14, 2025
Drugit: crowd-sourcing molecular design of non-peptidic VHL bindersThomas Scott, Christian Alan Paul Smethurst, Yvonne Westermaier, et al.
Nature Communications|October 10, 2022
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivoChristiane Kofink, Nicole Trainor, Barbara Mair, et al.
Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Nature Chemical Biology|June 11, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Nature Chemical Biology|July 4, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Nature Chemical Biology|July 23, 2021
HUWE1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domainDaniel B Grabarczyk, Olga A Petrova, Luiza Deszcz, et al.
Journal of Medicinal Chemistry|February 26, 2016
Structure-Based Design of an in Vivo Active Selective BRD9 InhibitorLaetitia J Martin, Manfred Koegl, Gerd Bader, et al.
Nature Communications|April 14, 2025
Drugit: crowd-sourcing molecular design of non-peptidic VHL bindersThomas Scott, Christian Alan Paul Smethurst, Yvonne Westermaier, et al.
Nature Communications|October 10, 2022
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivoChristiane Kofink, Nicole Trainor, Barbara Mair, et al.
Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Nature Chemical Biology|June 11, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Nature Chemical Biology|July 4, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Pageof 4